Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innovent Biologics ( (HK:1801) ) just unveiled an update.
Innovent Biologics announced that Jaypirca (pirtobrutinib), a highly selective non-covalent Bruton’s tyrosine kinase inhibitor developed by Eli Lilly and commercialized by Innovent in China, has been approved by the National Medical Products Administration for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least one prior BTK inhibitor-containing systemic therapy. The new indication, backed by positive Phase 3 BRUIN CLL-321 data showing superior progression-free survival and better tolerability versus standard regimens, strengthens Innovent’s oncology portfolio and is expected to enhance access to cutting-edge hematologic cancer treatments for Chinese patients, reinforcing the company’s position in the country’s rapidly evolving lymphoma treatment landscape.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$115.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a China-focused biopharmaceutical company specializing in oncology, with a portfolio centered on innovative biologic therapies. The company partners with global drug developers such as Eli Lilly to develop and commercialize advanced cancer treatments in the mainland China market.
Average Trading Volume: 11,740,620
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$153.7B
Find detailed analytics on 1801 stock on TipRanks’ Stock Analysis page.